Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT04203381·Not applicable·INTERVENTIONAL

Skeletal Health and Bone Marrow Composition Among Youth

LeuprolideOtherTerminated

Status

Terminated

Phase

Not applicable

Enrollment

78

Locations

2

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Children and adolescents experiencing gender dysphoria feel increased distress with the onset of puberty. Gender clinics treat these young adolescents by "blocking" puberty using gonadotropin-releasing hormone (GnRH) agonist medications. This has the possibility of impacting bone development as sex steroids are important to bone mass development. In this multi-site study, the investigators will examine bone marrow composition (by MRI) in 40 transgender youth and bone density and body composition before/after pubertal blockade compared to healthy participants.

Full detailed description

The investigators propose to identify the effects of pubertal blockade on bone density and size in pediatric transgender individuals. Information is limited regarding bone health and metabolism for this group, and especially for children who are transgender. Further, the team's expertise in magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), dual-energy x-ray absorptiometry (DXA), and peripheral quantitative computed tomography (pQCT), examining the natal female skeleton in previous NIH funded studies, and extensive clinical expertise, provide an ideal foundation to apply this protocol to examine transgender female and transgender male skeleton. Findings from this study will allow us to identify potential preventative strategies to counter the long-term effects of puberty blockade such as osteoporosis and raise awareness of this medical consequence to medical care providers of transgender patients. The proposed project seeks to answer the clinically relevant question of how bone marrow composition relates to body composition, and its relation to both bone density and skeletal strength, in transgender patients who are undergoing puberty blockade, the first phase of therapy preceding gender-affirming hormone therapy.

Interventions

Treatment arms and agents.

DEVICE

GnRH Agonist

Forty participants who are transgender and who have been prescribed a gonadotropin-releasing hormone (GnRH) agonist by their physician will undergo magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) scans at baseline, at 12 months and at 24 months after initiation of the GnRH agonist therapy. This longitudinal observational study of two cohorts seeks to identify significant changes in bone marrow adiposity and bone density over 24 months. The same assessments will be obtained in 40 healthy control subjects matched for age, race/ethnicity and body mass index, all factors that are known to influence skeletal outcomes. The evaluations of bone marrow adiposity will be correlated with bone density measurements and the assessments of mood (validated anxiety and depression scales) and health-related quality of life, before and after pubertal blockade.

Timeline

From registration to results.

  1. First posted

    Dec 18, 2019

  2. Study start

    Sep 15, 2020

  3. Primary completion

    Mar 30, 2026

  4. Study completion

    Mar 30, 2026

  5. Results posted

    Not reported

  6. Registry updated

    Apr 3, 2026

Outcomes

What the study measures.

Primary outcomes

Change from Bone marrow adiposity by magnetic resonance imaging (MRI) from baseline compared to 24 months

Time frame · Change from baseline compared to 24 months

Change from bone marrow adiposity measured by MRI (T1 maps) from baseline compared to 24 months

Change from magnetic resonance spectroscopy (MRS) from baseline compared to 24 months

Time frame · Change from baseline compared to 24 months

Change from T2 corrected fat/(fat+ water) ratios from baseline compared to 24 months

Secondary outcomes

Change from total body bone mineral density Z-score by Dual-energy X-ray absorptiometry (DXA) from baseline compared to 24 months

Time frame · Change from baseline compared to 24 months

Change from total body BMD Z-score from baseline compared to 24 months

Change from spine BMD Z-score by DXA from baseline compared to 24 months

Time frame · Change from baseline compared to 24 months

Change from lumbar spine BMD Z-score from baseline compared to 24 months

Change from hip BMD Z-score by DXA from baseline compared to 24 months

Time frame · Change from baseline compared to 24 months

Change from hip bone mineral density (g/cm2) from baseline compared to 24 months

Change from volumetric bone mineral density (vBMD) from baseline compared to 24 months

Time frame · Change from baseline compared to 24 months

Change from quantitative computed tomography (pQCT) scans will be obtained at sites 3%, 38%, and 66% of tibial length proximal to the distal growth plate from baseline compared to 24 months

Change from section modulus (bone bending strength) by quantitative computed tomography (pQCT) from baseline compared to 24 months

Time frame · Change from baseline compared to 24 months

Change from pQCT scans will be obtained at sites 3%, 38%, and 66% of tibial length proximal to the distal growth plate from baseline compared to 24 months

Eligibility

Who can take part.

Minimum age
9 Years
Maximum age
14 Years
Sex
ALL
Healthy volunteers
Yes

Inclusion Criteria: 1. Be willing to give informed consent/assent (parent or legal guardian able to provide informed consent) 2. Tanner Stage II/III 3. Age 9-14 years old for assigned male at birth (AMAB) and 9-13 for assigned female at birth (AFAB) 4. Current patient at the Boston Children's Hospital Transgender Clinic or Cincinnati Children's Hospital Medical Center Clinic, within six weeks of initiating pubertal blockade treatment (e.g., GnRH agonist- Lupron or Vantas) 5. Controls are matched on age within 2 years, race/ethnicity, sex assigned at birth and BMI within 25% Exclusion Criteria: The participant must not: 1. Have chronic disease known to affect skeletal metabolism (e.g. cystic fibrosis, celiac disease, sickle cell disease, inflammatory bowel disease etc.) 2. Receipt of other medications within previous 3 months known to affect skeletal metabolism (e.g., glucocorticoids, anticonvulsants, etc.) 3. Have metal implants or hardware in their body that would not allow them to get an MRI 4. Have a diagnosis of a developmental disorder or claustrophobia that would prevent them from undergoing an MRI

Study locations

2 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Boston Children's Hospital

Boston, Massachusetts, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Leuprolide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsLeuprolide trial dashboard →